ClinicalTrials.gg
CompletedNCT02673489Updated May 8, 2018Results posted

A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

A Phase 3 interventional study of DCV and SOF in Hepatitis C, sponsored by Bristol-Myers Squibb. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-08.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing daclatasvir in Hepatitis C — 1 open to participants now, 2 under way, 1 of them phase 3. daclatasvir · Hepatitis C.

Enrollment
28th of 59
106 · median 100
Started
2016
with 4 others
Phase 3
24 of 59
none open now
Registered
50th of 59
by date
Lead sponsor
42 of 59
Bristol-Myers Squibb

Among the 59 studies testing daclatasvir in Hepatitis C, this one is the 28th largest by enrollment, is one of 5 that started in 2016, is one of 24 in phase 3, and was the 50th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 59 studies testing daclatasvir in Hepatitis C is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About daclatasvir

daclatasvir: first FDA approval 2015 (DAKLINZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing daclatasvir in Hepatitis C, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients with liver cirrhosis.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Genotype 3
  • HCV RNA ≥10000 IU (International Unit)/mL
  • Compensated Liver Cirrhosis
  • 18-40 kg/m2
  • Previously treated for HCV or never treated for HCV

Exclusion criteria

Exclusion Criteria:

  • Infection with other than Genotype 3. Mixed infection of any genotype
  • Evidence of decompensated liver disease
  • Previous exposure to NS5A inhibitors

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)

    Oral dosing of DCV 60 mg tablet once daily + SOF 400 mg tablet once daily + RBV 1000-1200 mg tablet per day (weight based) for 24 weeks.

    Drug: DCV · Drug: SOF · Drug: RBV

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR12)

    SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria and the Next Value Carried Backwards approach.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieve SVR12 in the Presence and Absence of Baseline NS5A (Non-structural Protein 5A) Resistance-associated Polymorphisms

    SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria and the Next Value Carried Backwards approach.

    Time frame: Week 12 (Follow-up period)

  2. Percentage of Subjects Who Achieve HCV RNA < LLOQ, TD or TND Through Follow up Week 24

    HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria. SVR12 is based on Next Value Carried Backwards approach.

    Time frame: At Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, End of Treatment (24 weeks), Follow Up Week 4 (28 weeks), Follow Up Week 12 (36 weeks), Follow Up Week 24 (48 weeks)

  3. Percentage of Subjects Who Achieve HCV RNA < LLOQ, TND Through Follow up Week 24

    HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria.

    Time frame: At Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, End of Treatment, Follow Up Week 4, Follow Up Week 12, Follow Up Week 24

07

Results

Posted Mar 29, 2018

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneTreatment NaiveTreatment Experienced
Started5424
Completed4921
Not completed53
Withdrew: Lost to follow-up30
Withdrew: Participant request to discontinue11
Withdrew: Participant moved to another province10
Withdrew: Participant was incarcerated01
Withdrew: Adverse event01
Follow Up Period
Participant flow — Follow Up Period
MilestoneTreatment NaiveTreatment Experienced
Started5023
Completed5021
Not completed02
Withdrew: Unable to return for week 24 follow-up01
Withdrew: Unable to return for follow-up01

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR12)

SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria and the Next Value Carried Backwards approach.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR12)
Percentage of participantsHCV Treatment NaiveHCV Treatment Experienced
Percentage of Participants With Sustained Virologic Response (SVR12)92.6 (82.1 to 97.9)75.0 (53.3 to 90.2)
SecondaryPercentage of Participants Who Achieve SVR12 in the Presence and Absence of Baseline NS5A (Non-structural Protein 5A) Resistance-associated Polymorphisms

SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria and the Next Value Carried Backwards approach.

Time frame:
Week 12 (Follow-up period)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve SVR12 in the Presence and Absence of Baseline NS5A (Non-structural Protein 5A) Resistance-associated Polymorphisms
Percentage of participantsHCV Treatment NaiveHCV Treatment Experienced
NS5A-Y93 Polymorphism: YES85.7 (42.1 to 99.6)0.0 (0.0 to 97.5)
NS5A-Y93 Polymorphism: NO93.6 (82.5 to 98.7)78.3 (56.3 to 92.5)
SecondaryPercentage of Subjects Who Achieve HCV RNA < LLOQ, TD or TND Through Follow up Week 24

HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria. SVR12 is based on Next Value Carried Backwards approach.

Time frame:
At Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, End of Treatment (24 weeks), Follow Up Week 4 (28 weeks), Follow Up Week 12 (36 weeks), Follow Up Week 24 (48 weeks)
Reported as:
Number · Percentage
Percentage of Subjects Who Achieve HCV RNA < LLOQ, TD or TND Through Follow up Week 24
PercentageHCV Treatment NaiveHCV Treatment Experienced
Week 114.8 (6.6 to 27.1)12.5 (2.7 to 32.4)
Week 250.0 (36.1 to 63.9)54.2 (32.8 to 74.4)
Week 492.6 (82.1 to 97.9)75.0 (53.3 to 90.2)
Week 898.1 (90.1 to 100.0)91.7 (73.0 to 99.0)
Week 1292.6 (82.1 to 97.9)87.5 (67.6 to 97.3)
Week 1690.7 (79.7 to 96.9)83.3 (62.6 to 95.3)
Week 2094.4 (84.6 to 98.8)83.3 (62.6 to 95.3)
Week 2488.9 (77.4 to 95.8)87.5 (67.6 to 97.3)
End of Treatment100.0 (93.4 to 100.0)91.7 (73.0 to 99.0)
Follow Up Week 488.9 (77.4 to 95.8)79.2 (57.8 to 92.9)
Follow Up Week 12 (Imputed)92.6 (82.1 to 97.9)75.0 (53.3 to 90.2)
Follow Up Week 2492.6 (82.1 to 97.9)66.7 (44.7 to 84.4)
SecondaryPercentage of Subjects Who Achieve HCV RNA < LLOQ, TND Through Follow up Week 24

HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria.

Time frame:
At Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, End of Treatment, Follow Up Week 4, Follow Up Week 12, Follow Up Week 24
Reported as:
Number · Percentage
Percentage of Subjects Who Achieve HCV RNA < LLOQ, TND Through Follow up Week 24
PercentageHCV Treatment NaiveHCV Treatment Experienced
Week 11.9 (0.0 to 9.9)0.0 (0.0 to 14.2)
Week 211.1 (4.2 to 22.6)12.5 (2.7 to 32.4)
Week 464.8 (50.6 to 77.3)62.5 (40.6 to 81.2)
Week 894.4 (84.6 to 98.8)83.3 (62.6 to 95.3)
Week 1290.7 (79.7 to 96.9)83.3 (62.6 to 95.3)
Week 1690.7 (79.7 to 96.9)79.2 (57.8 to 92.9)
Week 2094.4 (84.6 to 98.8)83.3 (62.6 to 95.3)
Week 2488.9 (77.4 to 95.8)83.3 (62.6 to 95.3)
End of Treatment100.0 (93.4 to 100.0)87.5 (67.6 to 97.3)
Follow Up Week 488.9 (77.4 to 95.8)79.2 (57.8 to 92.9)
Follow Up Week 1290.7 (79.7 to 96.9)75.0 (53.3 to 90.2)
Follow Up Week 2490.7 (79.7 to 96.9)66.7 (44.7 to 84.4)

Adverse events

Collected over From first dose until last dose plus 7 days (assessed up to May 2017, approximately 14 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall: Daclatasvir(DCV) + Sofosbuvir(SOF) + Ribavirin(RBV)0/78 (0%)8/78 (10.3%)63/78 (80.8%)
HCV Treatment Naive0/54 (0%)4/54 (7.4%)44/54 (81.5%)
HCV Treatment Experienced0/24 (0%)4/24 (16.7%)19/24 (79.2%)
Most frequent serious events
Most frequent serious events
EventOverall: Daclatasvir(DCV) + Sofosbuvir(SOF) + Ribavirin(RBV)HCV Treatment NaiveHCV Treatment Experienced
CholecystitisHepatobiliary disorders1/780/541/24
Streptococcal bacteraemiaInfections and infestations1/780/541/24
Accidental overdoseInjury, poisoning and procedural complications2/781/541/24
DepressionPsychiatric disorders1/780/541/24
AscitesGastrointestinal disorders1/781/540/24
Chest discomfortGeneral disorders1/781/540/24
BronchiolitisInfections and infestations1/781/540/24
OverdoseInjury, poisoning and procedural complications1/781/540/24
Most frequent other events
Showing 10 of 22
Most frequent other events
EventOverall: Daclatasvir(DCV) + Sofosbuvir(SOF) + Ribavirin(RBV)HCV Treatment NaiveHCV Treatment Experienced
FatigueGeneral disorders34/7821/5413/24
HeadacheNervous system disorders22/7814/548/24
NauseaGastrointestinal disorders19/7813/546/24
InsomniaPsychiatric disorders14/7811/543/24
AnaemiaBlood and lymphatic system disorders10/786/544/24
DizzinessNervous system disorders6/783/543/24
IrritabilityPsychiatric disorders7/786/541/24
ToothacheGastrointestinal disorders5/783/542/24
ArthralgiaMusculoskeletal and connective tissue disorders5/783/542/24
AnxietyPsychiatric disorders5/783/542/24

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Treatment NaiveTreatment ExperiencedTotal
Mean54 ± 7.9755.3 ± 4.9054.4 ± 7.16
Sex: Female, Male
Sex: Female, Male(Participants)Treatment NaiveTreatment ExperiencedTotal
Female14721
Male401757
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment NaiveTreatment ExperiencedTotal
Hispanic or Latino7613
Not Hispanic or Latino20828
Unknown or Not Reported271037
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment NaiveTreatment ExperiencedTotal
American Indian or Alaska Native202
Asian437
Native Hawaiian or Other Pacific Islander000
Black or African American000
White482169
More than one race000
Unknown or Not Reported000
08

Study locations

19 sites
  • Keck Medical Center Of USC
    Los Angeles, California 90033, United States
  • University Of California, San Francisco
    San Francisco, California 94143, United States
  • Gastrointestinal Specialists of Georgia, PC
    Marietta, Georgia 30060, United States
  • Ruth Rothstein Core Center
    Chicago, Illinois 60612, United States
  • Digestive Disease Associates, PA
    Catonsville, Maryland 21228, United States
  • Northeast Clinical Research Center
    Bethlehem, Pennsylvania 18017, United States
  • University Gastroenterology
    Providence, Rhode Island 02905, United States
  • Texas Clinical Research Institute
    Arlington, Texas 76012, United States
  • Methodist Transplant Physicians
    Dallas, Texas 75203, United States
  • The Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Bon Secours St. Mary's Hospital of Richmond, Inc
    Richmond, Virginia 23226, United States
  • Local Institution
    Calgary, Alberta T2N 4Z6, Canada
  • Local Institution
    Edmonton, Alberta T6G 2P4, Canada
  • Local Institution
    Vancouver, British Columbia V6Z 2K5, Canada
  • Local Institution
    Victoria, British Columbia V8V 3P9, Canada
  • Local Institution
    Toronto, Ontario M5G 2C4, Canada
  • Local Institution
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution
    Regina, Saskatchewan S4O 0W5, Canada
09

References and documents

Publications

  • Poordad F, Shiffman ML, Ghesquiere W, Wong A, Huhn GD, Wong F, Ramji A, Shafran SD, McPhee F, Yang R, Noviello S, Linaberry M; ALLY-3C study team. Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C). Antivir Ther. 2019;24(1):35-44. doi: 10.3851/IMP3278. PubMed 30382942 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Mar 2017, 11 months.

Results were first posted in Mar 2018, 1 year after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 11 months is below that.

Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2016
First posted
Feb 4, 2016
StartActual
Mar 15, 2016
Primary completionActual
Mar 2, 2017
CompletionActual
May 26, 2017
Results first posted
Mar 29, 2018
Last update
May 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02673489
Responsible party
Sponsor
First posted
Feb 4, 2016
Start date
Mar 15, 2016
Primary completion
Mar 2, 2017
Completion
May 26, 2017
Results posted
Mar 29, 2018
Last update
May 8, 2018

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daclatasvir · Sofosbuvir · Ribavirin

Start the discussion